Gekko Brief
AI summaryNov 9 close
AbCellera reports third-quarter results, with a loss that tops revenue estimates and compares to a loss of $0.19 per share a year ago. Investor attention centers on ABCL635, the antibody targeting vasomotor symptoms in postmenopausal women, following positive Phase 2 data that management and observers describe as a crucial clinical signal for the company's antibody discovery platform. The company also announced it will present at the UBS Global Biopharma Conference on 17 November 2026.
Shares close at $12.50, up 5.2%, sitting above both the 50-day average of $12.30 and the 200-day average of $7.08, with the 50-day above the 200-day. The GekkoIndex reads 57.6, placing the stock in the Neutral zone after slipping 3 points over five sessions. Gekko Fair Value stands at $14.24, putting the current price 12.2% below that mark. One-year return sits at 175.9%, though the one-month return is slightly negative at -0.4%.
No confirmed earnings date currently appears on the calendar, following the last report on 5 August 2026, which beat estimates and produced a 7.2% reaction. Over the last 90 days, 4 open-market insider purchases totaling $1,545,679 have been recorded, alongside 1 unusual options signal in the last 30 days, with call premium of $280,416 and no put premium. Analyst coverage from 7 firms shows 6 buy ratings, 1 hold, and a consensus target of $17.17. Seasonality over the next 20 trading days has averaged -0.8% across 5 years, rising in 2 of them.